Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database-Reference-Cited by-同舟云学术

Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database

Published:2021-06-28 Issue:9 Volume:20 Page:1125-1136
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Charan Jaykaran¹^ORCID,Dutta Siddhartha¹^ORCID,Kaur Rimplejeet¹,Bhardwaj Pankaj²,Sharma Praveen³^ORCID,Ambwani Sneha¹,Jahan Iffat⁴^ORCID,Abubakar Abdullahi Rabiu⁵,Islam Salequl⁶^ORCID,Hardcastle Timothy Craig⁷^ORCID,Rahman Nor Azlina A⁸^ORCID,Lugova Halyna⁹,Haque Mainul¹⁰^ORCID

Affiliation:

1. Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India

2. Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India

3. Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India

4. Department of Physiology, Eastern Medical College, Cumilla, Bangladesh

5. Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Bayero University, Kano, Nigeria

6. Department of Microbiology, Jahangirnagar University, Savar, Dhaka, Bangladesh

7. Department of Surgery, Nelson R Mandela School of Clinical Medicine, University of KwaZulu-Natal, Umbel, Berea, South Africa

8. Department of Physical Rehabilitation Sciences, Kulliyyah of Allied Health Sciences, International Islamic University Malaysia, Kuantan, Malaysia

9. Unit of Community Medicine. Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sungai Besi, Kuala Lumpur, Malaysia

10. Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sungai Besi, Kuala Lumpur, Malaysia

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2021.1946513

Reference66 articles.

1. World Health Organization. Transmission of SARS-CoV-2: implications for infection prevention precautions. Updated 9 July 2020. [cited 2020 Oct 20]. https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions

2. World Health Organization. Rolling updates on coronavirus disease (COVID-19). Updated 31 Jul 2020. [cited 2020 Oct 20]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen

3. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Updated 20 Oct 2020. [cited 2020 Oct 20]. https://covid19.who.int

4. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

5. Clinical and immunological features of severe and moderate coronavirus disease 2019

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccination strategies for patients under monoclonal antibody and other biological treatments: an updated comprehensive review based on EMA authorizations to January 2024;Expert Review of Vaccines;2024-09-11

2. Association of COVID with Mycosis in General;Infectious Disorders - Drug Targets;2024-09

3. Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study;Expert Opinion on Drug Safety;2024-07-25

4. A Systematic Analysis of COVID-19 Clinical Trials Registered in the Clinical Trials Registry of India;Cureus;2024-04-09

5. Self-reported side effects of COVID-19 vaccines among health professions students in India;PeerJ;2024-04-05